Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Determinants of Adherence to a Ketogenic Diet in Patients with Heart Failure with Reduced Ejection Fraction.

Nutrients·2026

Same author

Closing the digital divide for hemodialysis patients: implementing technology training and support in a digital patient activation intervention.

Journal of the American Medical Informatics Association : JAMIA·2026

Same author

Sexual wellbeing support for men with prostate cancer: a qualitative study with patients.

Translational andrology and urology·2025

Same author

Supporting mental health recovery in patients with heart disease: a commentary.

European journal of cardiovascular nursing·2024

Same author

Visual pathology reports for improved collaboration at multidisciplinary head and neck tumor board.

Head & neck·2024

Same author

Qualitative Classification of Late Systemic Symptoms in Head and Neck Cancer Survivors.

Cancers·2024

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Peptide-mediated immunosuppression.

Weiping Zang¹, Barbara Murphy

¹Renal Division, Mount Sinai School of Medicine, NY 10029, USA.

American Journal of Therapeutics

|November 11, 2005

Summary

This summary is machine-generated.

Synthetic peptides from conserved MHC class II regions can modulate immune responses. These peptides induce apoptosis in antigen-presenting cells (APCs) and suppress T-cell activity, offering potential therapies for immune-mediated diseases.

More Related Videos

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Related Experiment Videos

Last Updated: Jan 18, 2026

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Area of Science:

Immunology
Molecular Biology
Immunotherapy

Background:

Synthetic peptides and analogues show potential in modulating immune responses.
Class II Major Histocompatibility Complex (MHC) alpha chain conserved regions are key targets.
Understanding immunomodulation mechanisms is crucial for developing new therapies.

Purpose of the Study:

To investigate the immunomodulatory role of synthetic peptides from conserved regions of the class II MHC alpha chain.
To elucidate the mechanisms by which these peptides inhibit immune responses.
To assess the in vitro and in vivo efficacy of these peptides in preventing immune reactions.

Main Methods:

Studied synthetic peptides derived from conserved regions of the class II MHC alpha chain.
Assessed inhibition of mixed lymphocyte response (MLR), autoantigen proliferation, cytokine production, and cytolytic T lymphocyte (CTL) generation in rat, human, and mouse models.
Investigated the induction of apoptosis in antigen-presenting cells (APCs) via a caspase-independent pathway.
Evaluated the hyporesponsiveness of T lymphocytes stimulated with HLA-DQA1.
Tested in vivo efficacy in a murine delayed-type hypersensitivity (DTH) model.

Main Results:

MHC-derived peptides inhibited MLR, autoantigen proliferation, cytokine production, and CTL generation.
The inhibitory effect was mediated by inducing apoptosis in APCs through a nonclassic caspase-independent pathway.
T lymphocytes stimulated with HLA-DQA1 became hyporesponsive to subsequent stimuli.
In vivo, HLA-DQA1 prevented priming and effector function of allogeneic T cells in a murine DTH model.

Conclusions:

Peptides from conserved class II MHC alpha chain regions effectively alter T-lymphocyte immune responses both in vitro and in vivo.
These findings suggest a novel therapeutic approach for immune-mediated diseases.
The mechanism involves APC apoptosis and T-cell hyporesponsiveness, highlighting targeted immunomodulation strategies.